Mark Spiecker

Mark Spiecker leads Sharklet Technologies, Inc. and its joint venture, Clearsight, LLC, which is developing the first intraocular lens featuring the microorganism-inhibiting Sharklet micro-texture to reduce the incidence of PCO. Prior to becoming CEO at Sharklet Technologies, Spiecker held a variety of leadership roles at high-tech and telecommunications companies. He is an active community leader serving as Chairman of the Board of the Colorado Biosciences Association (CBSA) and a Board Member of the Denver Metro Chamber of Commerce. Spiecker earned an MBA and a BSBA in Marketing from Rockhurst University.